Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N•SAS-BC 01 trial and CUBC trial)

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 633-641

  Ohashi, Yasuo ^a   Watanabe, Toru ^b   Sano, Muneaki ^c   Koyama, Hiroki ^d   Inaji, Hideo ^d   Suzuki, Takaichiro ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Hamamatsu Oncology Center   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Adjuvant chemotherapy; Breast cancer; CMF; Estrogen receptor positive breast cancer; Pooled analysis; UFT

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; UFT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EARLY CANCER; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ESTROGEN; TEGAFUR; URACIL; YOUNG ADULT;

EID: 74849108808     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0635-3     Document Type: Article

References (27)

1. M Clarke AS Coates SC Darby C Davies RD Gelber J Godwin A Goldhirsch R Gray R Peto KI Pritchard WC Wood 2008 Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials Lancet 371 9606 29 40 10.1016/S0140-6736(08)60069-0 10.1016/S0140- 6736(08)60069-0 1:STN:280:DC%2BD1c%2FhtFGqtw%3D%3D 18177773
2. T Nakajima T Kinoshita A Nashimoto M Sairenji T Yamaguchi J Sakamoto T Fujiya T Inada M Sasako Y Ohashi 2007 Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer Br J Surg 94 12 1468 1476 10.1002/bjs.5996 10.1002/bjs.5996 1:CAS:528:DC%2BD1cXhtFKhurk%3D 17948223 (Pubitemid 350275624)
3. T Akasu Y Moriya Y Ohashi S Yoshida K Shirao S Kodaira 2006 Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial Jpn J Clin Oncol 36 4 237 244 10.1093/jjco/hyl014 10.1093/jjco/hyl014 16675478
4. H Kato Y Ichinose M Ohta E Hata N Tsubota H Tada Y Watanabe H Wada M Tsuboi N Hamajima 2004 A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 17 1713 1721 10.1056/NEJMoa032792 10.1056/NEJMoa032792 1:CAS:528:DC%2BD2cXjt12mt7c%3D 15102997 (Pubitemid 38501140)
5. BC Lembersky HS Wieand NJ Petrelli MJ O'Connell LH Colangelo RE Smith TE Seay JK Giguere ME Marshall AD Jacobs LK Colman A Soran G Yothers N Wolmark 2006 Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast And Bowel Project Protocol C-06 J Clin Oncol 24 13 2059 2064 10.1200/JCO.2005.04.7498 10.1200/JCO.2005.04.7498 1:CAS:528: DC%2BD28Xlt1amurk%3D 16648506 (Pubitemid 46622115)
6. K Ota T Taguchi K Kimura 1988 Report on nationwide pooled data and cohort investigation in UFT phase II study Cancer Chemother Pharmacol 22 4 333 338 10.1007/BF00254241 1:STN:280:DyaL1M%2FgtlCjtA%3D%3D 3139315
7. H Tashiro Y Nomura A Ohsaki 1994 A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer Jpn J Clin Oncol 24 4 212 217 1:STN:280:DyaK2czltF2gug%3D%3D 8072200
8. F Kasumi M Yoshimoto J Uchino R Abe Y Nomura K Sugimachi H Nakazato O Abe 2003 Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer Oncology 64 2 146 153 10.1159/000067763 10.1159/000067763 1:CAS:528:DC%2BD3sXntFShsA%3D%3D 12566912 (Pubitemid 36173380)
9. S Noguchi H Koyama J Uchino R Abe S Miura K Sugimachi K Akazawa O Abe 2005 Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials J Clin Oncol 23 10 2172 2184 10.1200/JCO.2005.02.158 10.1200/JCO.2005.02.158 1:CAS:528:DC%2BD2MXjsVyiu70%3D 15800310 (Pubitemid 46218709)
10. T Watanabe M Sano S Takashima T Kitaya Y Tokuda M Yoshimoto N Kohno K Nakagami H Iwata K Shimozuma H Sonoo H Tsuda G Sakamoto Y Ohashi 2009 Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial J Clin Oncol 27 9 1368 1374 10.1200/JCO.2008.18.3939 10.1200/JCO.2008.18. 3939 1:CAS:528:DC%2BD1MXksF2iu70%3D 19204202
11. Y Park K Okamura S Mitsuyama T Saito J Koh S Kyono K Higaki M Ogita T Asaga H Inaji H Komichi N Kohno K Yamazaki F Tanaka T Ito H Nishikawa A Osaki H Koyama T Suzuki 2009 Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study Br J Cancer 101 4 598 604 10.1038/sj.bjc.6605218 10.1038/sj.bjc.6605218 1:CAS:528:DC%2BD1MXpvFyis7Y%3D 19638976
12. Y Hochberg 1988 A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 4 800 802 10.1093/biomet/75.4.800 10.1093/biomet/75.4.800
13. G Bonadonna P Valagussa A Moliterni M Zambetti C Brambilla 1995 Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 14 901 906 10.1056/NEJM199504063321401 1:STN:280:DyaK2M7otlSqsg%3D%3D 7877646
14. Nakamura S, Abe O, Ikeda T, Toi M (2006) Postoperative adjuvant therapy with tamoxifen, tegafur-uracil (UFT), or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials (relapse-free survival data). Proc Am Soc Clin Oncol 24:18s (abstr 633)
15. HB Muss DA Berry CT Cirrincione M Theodoulou AM Mauer AB Kornblith AH Partridge LG Dressler HJ Cohen HP Becker PA Kartcheske JD Wheeler EA Perez AC Wolff JR Gralow HJ Burstein AA Mahmood G Magrinat BA Parker RD Hart D Grenier L Norton CA Hudis EP Winer 2009 Adjuvant chemotherapy in older women with early-stage breast cancer N Engl J Med 360 20 2055 2065 10.1056/NEJMoa0810266 10.1056/NEJMoa0810266 1:CAS:528:DC%2BD1MXmtVagsbw%3D 19439741
16. J Kurebayashi M Nukatsuka H Nagase T Nomura M Hirono Y Yamamoto Y Sugimoto T Oka H Sonoo 2007 Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells Cancer Chemother Pharmacol 59 4 515 525 10.1007/s00280-006-0293-7 10.1007/s00280-006-0293-7 1:CAS:528: DC%2BD2sXlslahsg%3D%3D 16900372 (Pubitemid 46122330)
17. Kurebayashi J, Nukatsuka M, Sonoo H, Uchida J, Kiniwa M (2009) Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. Cancer Chemother Pharmacol. doi: 10.1007/s00280-009-1024-7
18. M Toi T Ikeda F Akiyama M Kurosumi H Tsuda G Sakamoto O Abe 2007 Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy Int J Oncol 31 4 899 906 1:CAS:528:DC%2BD2sXht1SjurfP 17786323
19. A Gennari MP Sormani P Pronzato M Puntoni M Colozza U Pfeffer P Bruzzi 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 1 14 20 10.1093/jnci/djm252 1:CAS:528:DC%2BD1cXit1Cku7o%3D 18159072 (Pubitemid 351767337)
20. DA Berry C Cirrincione IC Henderson ML Citron DR Budman LJ Goldstein S Martino EA Perez HB Muss L Norton C Hudis EP Winer 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 14 1658 1667 10.1001/jama.295.14.1658 10.1001/jama.295.14.1658 1:CAS:528:DC%2BD28XjsVeqs7k%3D 16609087
21. DF Hayes AD Thor LG Dressler D Weaver S Edgerton D Cowan G Broadwater LJ Goldstein S Martino JN Ingle IC Henderson L Norton EP Winer CA Hudis MJ Ellis DA Berry 2007 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 15 1496 1506 10.1056/NEJMoa071167 10.1056/NEJMoa071167 1:CAS:528:DC%2BD2sXhtFKmurrO 17928597 (Pubitemid 47572635)
22. P Ellis P Barrett-Lee L Johnson D Cameron A Wardley S O'Reilly M Verrill I Smith J Yarnold R Coleman H Earl P Canney C Twelves C Poole D Bloomfield P Hopwood S Johnston M Dowsett JM Bartlett I Ellis C Peckitt E Hall JM Bliss 2009 Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Lancet 373 9676 1681 1692 10.1016/S0140-6736(09)60740-6 10.1016/S0140-6736(09)60740-6 1:CAS:528: DC%2BD1MXmtVWjtL0%3D 19447249
23. VM Duric MR Stockler S Heritier F Boyle J Beith A Sullivan N Wilcken AS Coates RJ Simes 2005 Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16 11 1786 1794 10.1093/annonc/mdi370 10.1093/annonc/mdi370 1:STN:280:DC%2BD2MrlvFGlsg%3D%3D 16126738 (Pubitemid 41631241)
24. JL Yen-Revollo RM Goldberg HL McLeod 2008 Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 14 1 8 13 10.1158/1078-0432.CCR-07-1225 10.1158/1078-0432.CCR-07-1225 1:CAS:528:DC%2BD1cXoslOk 18172246
25. JA Sparano S Paik 2008 Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 5 721 728 10.1200/JCO.2007.15.1068 10.1200/JCO.2007.15.1068 18258979 (Pubitemid 351264384)
26. G Liu E Franssen MI Fitch E Warner 1997 Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1 110 115 1:STN:280:DyaK2s7kvFehsQ%3D%3D 8996131
27. MW Saif KN Syrigos NA Katirtzoglou 2009 S-1: a promising new oral fluoropyrimidine derivative Expert Opin Investig Drugs 18 3 335 348 10.1517/13543780902729412 10.1517/13543780902729412 1:CAS:528: DC%2BD1MXitlWrtL0%3D 19243284